Abstract
Dosing insulin is like a dance. The insulin dose is initially calculated, and then the blood glucose levels must be evaluated order to increase or decrease the insulin dose responsible for that blood glucose value. The goal is not to go chasing after the blood glucose has risen, but to prevent its rise. For this, one must carefully take into account the quality and quantity of a given meal (and its carbohydrate content), the activity level, the patient’s health status, and how other medications could affect the blood glucose levels.
In this chapter, we describe the different insulin types and their action times, the clinical indications for insulin initiation, the different insulin regimens, and the adverse effects. We also give insulin storage and injection recommendations.
Having a multidisciplinary team (diabetes educator, dietitian, physician, patient, family support) is key for insulin initiation and adjustment. Starting insulin in the office (first injection) will increase treatment adherence. Having a close follow-up is important. In addition, one must be careful to educate the patient in hypoglycemia prevention, detection, and treatment. It cannot be stressed enough that self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) and recording is key for a successful insulin therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
To access useful information and resources about the topic in Spanish consult. https://clinicaendi.mx/recursos-impresos/
References
Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract. 2005;18(3):199–204. http://www.ncbi.nlm.nih.gov/pubmed/15879567.
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–603.
American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, JEB R, Young-Hyman D, Das S, Kosiborod M. 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S83–96. https://doi.org/10.2337/dc22-S006.
Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm--2020 executive summary. Endocr Pract. 2020;26(1):107–39.
Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127(10):S25–38. https://doi.org/10.1016/j.amjmed.2014.07.005.
Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716.
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–47. https://doi.org/10.1056/NEJMoa0905479.
Riddle M, Rosenstock J, Gerich J. The treat-to-target trial. Diabetes Care. 2003;26(11):3080–6.
Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and Pharmacodynamic characteristics of fast-acting insulin Aspart in adults with type 1 diabetes. Clin Pharmacokinet. 2017;56(5):551–9.
Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41(5):733–55. PMID: 32396624; PMCID: PMC7366348. https://doi.org/10.1210/endrev/bnaa015.
FDA approves Rapid-Acting Insulin, Lyumjev, for Pump Use- Medscape. 2021.
Origin T, Investigators T. Basal insulin and cardiovascular and other outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319–28. https://doi.org/10.1056/NEJMoa1203858.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–32. https://doi.org/10.1056/NEJMoa1615692.
Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 unitszm L21 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 UnitszmL21. Diabetes Care. 2015;38(4):637–43.
Bailey T, Dahmen R, Pettus J, Roussel R, Bergmann K, Maroccia M, Nassr N, Klein O, Bolli G, Heise T. Insulin glargine 300 u/ml (gla-300) provides more stable and more evenly distributed steady-state pharmacodynamic/pharmacokinetic profiles compared with insulin degludec in type 1 diabetes (T1DM). Endocr Pract. 2017;23(1):48A. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L615078040.
Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL. Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Diabetes Obes Metab. 2017;19(7):1032–9.
Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frías JP, Roussel R, Bolli GB. More similarities than differences testing insulin glargine 300 units/mL versus insulin Degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care. 2018;41(10):2147–54. Epub 2018 Aug 13. https://doi.org/10.2337/dc18-0559.
Sorli C. New developments in insulin therapy for type 2 diabetes. Am J Med. 2014;127(10):S39–48. http://linkinghub.elsevier.com/retrieve/pii/S0002934314005865.
Klonoff DC. Afrezza inhaled insulin. J Diabetes Sci Technol. 2014;8(6):1071–3. https://doi.org/10.1177/1932296814555820.
Weiss S, Cheng S. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled. Arch Intern Med. 2003;163:2277–82. http://archinte.ama-assn.org/cgi/reprint/163/19/2277.pdf.
Arnolds S, Heise T. Inhaled insulin. Best Pract Res Clin Endocrinol Metab. 2007;21(4):555–71. http://linkinghub.elsevier.com/retrieve/pii/S1521690X07000590.
Mohanty RR, Das S. Inhaled insulin—current direction of insulin research. J Clin Diagn Res. 2017;11(4):OE01–2.
Meneghini L, Mersebach H, Kumar S, Svendsen A, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin Aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011;17(5):727–36. https://doi.org/10.4158/EP10367.OR.
Meneghini LF. Stepwise addition of prandial insulin. Lancet Diabetes Endocrinol. 2014;2(1):3–4. https://doi.org/10.1016/S2213-8587(13)70056-1.
Bode B, Kyllo J, Kaufman FR. Pumping protocol. A guide to insulin pump therapy initiation. 2007. https://s3.amazonaws.com/medtronic-hcp/Pumping%20Protocol%20-%20a%20Guide%20to%20Insulin%20Pump%20Therapy%20Initiation.pdf.
Walsh J, Roberts R, Bailey T. Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol. 2011;5(1):129–35.
Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. J Diabetes Sci Technol. 2010;4(5):1174–81.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. http://www.ncbi.nlm.nih.gov/pubmed/8366922.
DiMeglio LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pillay K, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):105–14.
Further Reading
American Diabetes Association (ADA). Practical insulin: a handbook for prescribing providers. 3rd ed; 2011.
Faradji Hazán RN. Indicar un Esquema Convencional e Intensivo de Insulina. In Sociedad Mexicana de Nutrición y Endocrinología: Taller de Atención Integral para Pacientes con Diabetes. Manual para Profesores y Manual para Alumnos. Chapter 14. 1st Edition. Editorial Permanyer. 2014.
Faradji Hazán RN, Díaz Barriga Menchaca AP, Antillón Ferreira, CA. Diabetes en la Población Pediátrica. In Dorantes y Martínez, SMNE: Endocrinología Clínica. 5th Edition. Editorial Manual Moderno. 2016. ISBN 9786074485554.
Faradji Hazán RN, Sainz de la Maza Viadero E, Hazán de Jacob y Levy E, Morales Alvarado E y Díaz Barriga Menchaca AP: Capítulo 11. Tratamiento integral de la Diabetes Tipo 1. En Ochoa Martínez C, Madero Fernández del Castillo MA y González Chávez A, SMNE, CMMI: Manual práctico del manejo de la diabetes mellitus y sus complicaciones. 2ª edición. Editorial Alfil. 2019.
Phillips P. Insulin and type 2 diabetes: a simple guide to prevent’stuff ups’. Aust Fam Physician. 2006;35(12):975–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Appendix: Initial Doses for Each Regimen
Appendix: Initial Doses for Each Regimen
Basal insulin :
0.2 units/kg/day or 10 Units (Usually in the Evening)
Conventional Insulin Regimen:
0.5 units/kg/day
Divide
Option A
2/3 in a.m. (2/3 NPH, 1/3 rapid or fast acting).
1/3 in p.m. (1/2 NPH, 1/2 rapid or fast acting).
Option B
1/3 before every meal (1/2 NPH, 1/2 rapid or fast acting).
Basal Bolus Insulin Regimen :
Fixed basal-bolus
0.5 units/kg/day
−50% for basal doses.
−50% for prandial doses, divided in three equal doses. One for each meal.
Flexible basal-bolus.
0.5 units/kg/day (Total Daily Dose: TDD)
−50% for basal doses.
−50% for prandial doses.
Insulin to Carbohydrate Ratio (I:CHO ratio).
I:CHO ratio = 450/TDD.
Prandial bolus: Total of carbohydrate grams/I:CHO ratio.
Correction Factor:
mg/dL: Correction Factor = 2000/TDD.
mmol/L: Correction Factor = 100/TDD.
Pre meal target glucose: Initially 150 mg/dL (~8 mmol/L), later on 120 mg/dL (~7 mmol/L). If the patient is stable and is able to identify hypoglycemia, target glucose could be lowered to 100 mg/dL (5.55 mmol/L).
Post meal target glucose: 180 mg/dL (10 mmol/L).
Correction bolus = (Current glucose – Target glucose)/Correction factor.
Total Bolus: Prandial Bolus + Correction Bolus.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Faradji, R.N., de la Maza, E.S., Menchaca, A.P.D.B., Sanromán, J.R.M. (2023). Use of Insulin in Outpatient Diabetes Management. In: Rodriguez-Saldana, J. (eds) The Diabetes Textbook. Springer, Cham. https://doi.org/10.1007/978-3-031-25519-9_37
Download citation
DOI: https://doi.org/10.1007/978-3-031-25519-9_37
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-25518-2
Online ISBN: 978-3-031-25519-9
eBook Packages: MedicineMedicine (R0)